PP2A: The Achilles Heal in MDS with 5q Deletion (Q27690852)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

PP2A: The Achilles Heal in MDS with 5q Deletion (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

David A Sallman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sheng Wei

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

23 September 2014

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

published in

Frontiers in Oncology

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

264

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

20 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Regulation of HDM2 activity by the ribosomal protein L11

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Genomic instability--an evolving hallmark of cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

International scoring system for evaluating prognosis in myelodysplastic syndromes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Revised international prognostic scoring system for myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Clinical effect of point mutations in myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Multiple pathways regulated by the tumor suppressor PP2A in transformation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

A structural basis for 14-3-3sigma functional specificity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Efficacy of lenalidomide in myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Distinct haematological disorder with deletion of long arm of no. 5 chromosome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

2 June 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFONC.2014.00264

Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172014

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

27 November 2018

1 reference

12 December 2020

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

12 December 2020

Gene expression profiling of CD34+cells in patients with the 5q− syndrome

1 reference

12 December 2020

The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts

1 reference

12 December 2020

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 reference

12 December 2020

Identifiers

DOI

10.3389/FONC.2014.00264

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

25295231

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295231%20AND%20SRC:MED&resulttype=core&format=json